The study demonstrated that additional anti-angiogenic therapy with anlotinib, which offers convenient oral dosing instead of intravenous infusion as with bevacizumab, provides a clear benefit in terms of PFS versus gefitinib monotherapy for patients with advanced NSCLC harboring EGFR activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.